Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations.

To the Editor:

We read with interest the recent article in which Fernandes et al found that neutralizing monoclonal antibody therapy was associated with favorable outcomes among kidney transplant recipients presenting with mild COVID-19. We agree that neutralizing monoclonal antibody treatment may be beneficial. However, we highlight that additional information on patients’ immunologic state would be useful, including recent receipt of other transplant immunosuppression and underlying health conditions that may impact the susceptibility to developing severe COVID-19. Additionally, we wondered if any of these individuals had experienced past SARS-CoV-2 infection. In combination with vaccination, prior infection may reduce the risk of severe COVID-19.